Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Seattle Genetics (SGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (151)	12/5/2016 8:35:05 PM
From: Miljenko Zuanic	Respond to of 161

Adcetris; looks like true synergistic activity with Opdivo for CHL: investor.seagen.com Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma (Abstract #1105, oral presentation at 4:30 p.m. PT) Data were reported from 42 patients with relapsed or refractory HL after failure of frontline therapy who received the combination regimen of ADCETRIS plus Opdivo. Patients were treated once every three weeks with up to four cycles of combination therapy. After completion of the fourth cycle of treatment, patients were eligible to undergo an autologous stem cell transplant (ASCT). The median age of patients was 37 years. The majority of patients (88 percent) were refractory or had progressed after receiving the standard of care frontline treatment ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine). Key findings presented include: Of 29 response-evaluable patients, 26 patients (90 percent) had an objective response, including 18 patients (62 percent) with a complete metabolic response and eight patients (28 percent) with a partial metabolic response. One patient (three percent) had stable disease and two patients (seven percent) had progressive disease.....